Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice

Alcoholism: Clinical and Experimental Research

Volumn 40, Issue 10, 2016, Pages 2247-2252

  Sørensen, Gunnar ^a   Caine, S Barak ^a   Thomsen, Morgane ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alcohol; Exendin 4; Glucagon Like Peptide 1; Intravenous Self Administration; Mouse

Indexed keywords

EXENDIN 4; ALCOHOL; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; INSTRUMENTAL CONDITIONING; MALE; MOUSE; NONHUMAN; PALATABILITY; PRIORITY JOURNAL; REINFORCEMENT; AGONISTS; ANIMAL; DRUG EFFECTS; DRUG SELF ADMINISTRATION; FOOD; INTRAVENOUS DRUG ADMINISTRATION; REWARD;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CONDITIONING, OPERANT; ETHANOL; FOOD; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; MALE; MICE; PEPTIDES; REWARD; SELF ADMINISTRATION; VENOMS;

EID: 84989313066     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.13199     Document Type: Article

References (46)

1. Alhadeff AL, Grill HJ (2014) Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding. Am J Physiol Regul Integr Comp Physiol 307:R465–R470.
2. Alhadeff AL, Rupprecht LE, Hayes MR (2012) GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153:647–658.
3. Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492–2500.
4. Baraboi ED, St-Pierre DH, Shooner J, Timofeeva E, Richard D (2011) Brain activation following peripheral administration of the GLP-1 receptor agonist Exendin-4. Am J Physiol Regul Integr Comp Physiol 301:R1011–R1024.
5. Caine SB, Collins GT, Thomsen M, Wright C, Lanier RK, Mello NK (2014) Nicotine-like behavioral effects of the minor tobacco alkaloids nornicotine, anabasine, and anatabine in male rodents. Exp Clin Psychopharmacol 22:9–22.
6. Caine SB, Thomsen M, Barrett AC, Collins GT, Grundt P, Newman AH, Butler P, Xu M (2012) Cocaine self-administration in dopamine D(3) receptor knockout mice. Exp Clin Psychopharmacol 20:352–363.
7. Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S (2015) Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab 4:718–731.
8. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP (2012) The glucagon-like peptide 1 (GLP-1) analogue, Exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32:4812–4820.
9. Egecioglu E, Engel JA, Jerlhag E (2013a) The glucagon-like peptide 1 analogue, Exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One 8:e69010.
10. Egecioglu E, Engel JA, Jerlhag E (2013b) The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One 8:e77284.
11. Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E (2013c) The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38:1259–1270.
12. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B (1993) Exendin-4 is a high potency agonist and truncated Exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650–19655.
13. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP (1995) Distribution of GLP-1 binding sites in the rat brain: evidence that Exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7:2294–2300.
14. Graham DL, Erreger K, Galli A, Stanwood GD (2013) GLP-1 analog attenuates cocaine reward. Mol Psychiatry 18:961–962.
15. Grahame NJ, Cunningham CL (1997) Intravenous ethanol self-administration in C57BL/6J and DBA/2J mice. Alcohol Clin Exp Res 21:56–62.
16. Grahame NJ, Low MJ, Cunningham CL (1998) Intravenous self-administration of ethanol in beta-endorphin-deficient mice. Alcohol Clin Exp Res 22:1093–1098.
17. Haney M, Spealman R (2008) Controversies in translational research: drug self-administration. Psychopharmacology 199:403–419.
18. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB (1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273:G920–G927.
19. JECFA (1970) Toxicological evaluation of some extraction solvents and certain other substances. Fourteenth report of the Joint FAO/WHO Expert Committee on Food Additives, FAO Nutrition Meetings Report Series, World Health Organization.
20. Kalra S, Kalra B, Sharma A (2011) Change in alcohol consumption following liraglutide initiation: a real life experience. Poster 1029 presented at the American Diabetes Association Annual Meeting, June 24–28, San Diego, CA.
21. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR (2012) The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, Exendin-4 and liraglutide. Neuropharmacology 62:1916–1927.
22. Kastin AJ, Akerstrom V (2003) Entry of Exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27:313–318.
23. McKay NJ, Galante DL, Daniels D (2014) Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats. J Neurosci 34:16417–16423.
24. Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261–280.
25. Nakade Y, Tsukamoto K, Iwa M, Pappas TN, Takahashi T (2007) Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats. Auton Neurosci 131:50–56.
26. Nakade Y, Tsukamoto K, Pappas TN, Takahashi T (2006) Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 1111:117–121.
27. Panlilio LV, Goldberg SR (2007) Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 102:1863–1870.
28. Richard JE, Anderberg RH, Goteson A, Gribble FM, Reimann F, Skibicka KP (2015) Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system. PLoS One 10:e0119034.
29. Rinaman L (2010) Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Res 1350:18–34.
30. SAMHSA (2014) Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health, U.S. Department of Health and Human Services, Rockville, MD.
31. Schmidt LS, Thomsen M, Weikop P, Dencker D, Wess J, Woldbye DP, Wortwein G, Fink-Jensen A (2011) Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice. Psychopharmacology 216:367–378.
32. Shirazi RH, Dickson SL, Skibicka KP (2013) Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS One 8:e61965.
33. Sirohi S, Schurdak JD, Seeley RJ, Benoit SC, Davis JF (2016) Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiol Behav 161:140–144.
34. Sørensen G, Reddy IA, Weikop P, Graham DL, Stanwood GD, Wortwein G, Galli A, Fink-Jensen A (2015) The glucagon-like peptide 1 (GLP-1) receptor agonist Exendin-4 reduces cocaine self-administration in mice. Physiol Behav 149:262–268.
35. Suchankova P, Yan J, Schwandt ML, Stangl BL, Caparelli EC, Momenan R, Jerlhag E, Engel JA, Hodgkinson CA, Egli M, Lopez MF, Becker HC, Goldman D, Heilig M, Ramchandani VA, Leggio L (2015) The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry 5:e583.
36. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP (1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848–R856.
37. Thomsen M, Caine SB (2005) Chronic intravenous drug self-administration in rats and mice. Curr Protoc Neurosci Chapter 9:Unit 9.20.
38. Thomsen M, Caine SB (2011) False positive in the intravenous drug self-administration test in C57BL/6J mice. Behav Pharmacol 22:239–247.
39. Thomsen M, Hall FS, Uhl GR, Caine SB (2009) Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J Neurosci 29:1087–1092.
40. Thomsen M, Woldbye DP, Wortwein G, Fink-Jensen A, Wess J, Caine SB (2005) Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. J Neurosci 25:8141–8149.
41. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that Exendin-4 is an agonist and Exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678–1682.
42. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72.
43. Vallöf D, Maccioni P, Colombo G, Mandrapa M, Jornulf JW, Egecioglu E, Engel JA, Jerlhag E (2016) The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 21:422–437.
44. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ (1993) Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665–673.
45. WHO (2014) Global Status Report on Alcohol and Health. WHO Press: Geneva, Switzerland.
46. Williams DL, Hyvarinen N, Lilly N, Kay K, Dossat A, Parise E, Torregrossa AM (2011) Maintenance on a high-fat diet impairs the anorexic response to glucagon-like-peptide-1 receptor activation. Physiol Behav 103:557–564.